Faricimab Biosimilar - Research Grade

Human

ANGPT2 + VEGFA

5mg/ml

IgG1-kappa-lambda

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

O15123;P15692

Blue ice

Dual neutralization of angiopoietin-2 (ANGPT2) and VEGF-A targets two cooperating drivers of pathological angiogenesis studied in retinal and vascular disease. This recombinant bispecific antibody is an unconjugated, non-therapeutic analog of faricimab, supplied for research use only. Manufactured to in vivo standards and purified to low endotoxin, it is offered in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. It is suited to dual ligand-neutralization assays, in vitro functional screening, and in vivo angiogenesis and ocular disease models, providing a dependable and reproducible research reagent.

vascular endothelial growth factor A, VEGF-A, VEGF_angiopoietin 2, Ang2

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.